تاثیر سن بر پاسخ غلظت سرمی ویسفاتین ومقاومت به انسولین به یک جلسه فعالیت استقامتی

نوع مقاله : علمی - پژوهشی

نویسندگان

1 دانشگاه شهید بهشتی

2 دانشگاه علامه طباطبایی

3 دانشگاه علوم پزشکی شهید بهشتی

چکیده

هدف: هدف از این تحقیق بررسی تاثیر سن بر پاسخ سرمی ویسفاتین و مقاومت به انسولین به یک جلسه فعالیت استقامتی بود. روش شناسی: چهل و پنج آزمودنی مرد به سه گروه سنی 15 نفری جوان (20- 30 سال. 9/22BMI:)، میانسال (40-50 سال،9/25:BMI) و مسن (60-70 سال، 4/26:BMI) تقسیم شدند. آزمودنی‌ها در همه گروهها ، پس از تعیین حداکثر اکسیژن مصرفی، 30 دقیقه فعالیت را با شدت 60 درصد توان هوازی خود بر روی دوچرخه انجام دادند و متعاقب آن 30 دقیقه ریکاوری غیر فعال داشتند. سه نمونه خونی قبل از فعالیت، بلافاصله بعد از فعالیت و نیز پس از 30 دقیقه گرفته شد و برای اندازه‌گیری گلوکز، انسولین، اینترلوکین-6 ویسفاتین آنالیز شدند. مقاومت به انسولین نیز با استفاده از غلظت گلوکز و انسولین محاسبه گردید. جهت بررسی اثر سن بر پاسخ فاکتورهای مختلف از آنوای یک راهه مستقل استفاده شد. نتایج: نتایج نشان داد که بین پاسخ سرمی ویسفاتین به فعالیت حاد استقامتی در گرو‌های سنی تفاوت معنی‌داری وجود دارد (001/0 =P) در حالی که تاثیر سن بر پاسخ گلوکز، انسولین، اینترلوکین -6 و شاخص مقاومت به انسولین به فعالیت معنی دار نبود (05/0P). بحث و نتیجه گیری: بر اساس نتایج تحقیق سن عامل موثری بر پاسخ سرمی ویسفاتین به فعالیت حاد استقامتی می‌باشد، و اینکه ویسفاتین در کاهش مقاومت به انسولین نقش ندارد بلکه احتمالا از طریق مسیرهای دیگری در تعادل انرژی نقش دارد.

کلیدواژه‌ها

مراجع

  1. منابع
  2. Wajchenberg BL. (2000). Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev.21(6):697-738.
  3. Mazzeo RS, Tanaka H. (2001). Exercise prescription for the elderly. Sports Medicine.31(11):809-18.
  4. Ahima RS. Adipose tissue as an endocrine organ. Obesity. 2006;14:242S-9S.
  5. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. (2006). Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. Journal of Clinical Endocrinology & Metabolism.91(8):3165-70.
  6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307(5708):426-30.
  7. Tanaka T, Nabeshima Y-i. (2007). Nampt/PBEF/ Visfatin: a new player in β cell physiology and in metabolic diseases? Cell Metab.6(5):341-3.
  8. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. (1994). Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol.14(2):1431-7.
  9. Frydelund-Larsen L, Akerstrom T, Nielsen S, Keller P, Keller C, Pedersen BK. (2007). Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. American Journal of Physiology-Endocrinology And Metabolism. 292(1):E24-E31.
  10. Sommer G, Garten A, Petzold S, Beck-Sickinger A, Bluher M, Stumvoll M, et al. (2008). Visfatin/ PBEF/ Nampt: structure, regulation and potential function of a novel adipokine. Clinical Science. 115:13-23.
  11. Haider D, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. (2006). The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia. 49(8):1909-14.
  12. Choi K, Kim J, Cho G, Baik S, Park H, Kim S. (2007). Effect of exercise training on plasma visfatin and eotaxin levels. European Journal of Endocrinology. 157(4):437-42.
  13. Kadoglou N, Fotiadis G, Kapelouzou A, Kostakis A, Liapis C, Vrabas I. (2013). The differential anti‐inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with Type 2 diabetes. Diabetic Medicine. 30(2):e41-e50.
  14. Lopez-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, et al. (2006). Serum visfatin increases with progressive β-cell deterioration. Diabetes. 55(10): 2871-5.
  15. Arner P. (2006). Editorial: Visfatin—A True Or False Trail To Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 91(1):28-30.
  16. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, Pace D, et al. (2007). Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. The American journal of clinical nutrition. 85(2):399-404.
  17. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. (2005). Plasma visfatin concentrations and fat depot–specific mRNA expression in humans. Diabetes. 54(10):2911-6.
  18. Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee M-J, et al. (2007). Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. Journal of Clinical Endocrinology & Metabolism. 92(2):666-72.
  19. Jürimäe J, Gruodytė R, Saar M, Cicchella A, Stefanelli C, Passariello C, et al. (2011). Plasma visfatin and adiponectin concentrations in physically active adolescent girls: relationships with insulin sensitivity and body composition variables. Journal of Pediatric Endocrinology and Metabolism. 24(7-8):419-25.
  20. Falah S, Kordi Mr, Ahmadizad S, Ravasi AA, Hedayati M. (1390). The effects of 8 weeks of endurance training on resting levels and responses of visfatin and insulin resistance index to acute endurance exercise in diabetics rats Sport Physiology & Management Investigations. 8.
  21. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Müller M, Wolzt M. (2006). Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. Journal of Clinical Endocrinology & Metabolism. 91(11):4702-4.
  22. Haus J, Solomon T, Marchetti C, O'Leary V, Gonzalez F, Kirwan J. (2009). Decreased visfatin after exercise training correlates with improved glucose tolerance. Medicine Science in Sports Exercise. 41(6):1255.
  23. Brema I, Hatunic M, Finucane F, Burns N, Nolan J, Haider D, et al. (2008). Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 10(7):600-2.
  24. Lai A, Chen W, Helm K. (2013). Effects of Visfatin Gene Polymorphism RS4730153 on Exercise-induced Weight Loss of Obese Children and Adolescents of Han Chinese. International journal of biological sciences. 9(1):16.
  25. Aggeloussi S, Theodorou AA, Paschalis V, Nikolaidis MG, Fatouros IG, Owolabi EO, et al. (2012). Adipocytokine levels in children: effects of fatness and training. Pediatr Exerc Sci. 24(3):461-71.
  26. Ahmadizad S, Rahmani H, Bassami M, Tahmasebi W. (1391). Relationship between resting plasma visfatin levels and its changes in response to acute endurance exercise with aerobic fitness and body composition in healthy men.
  27. JÜRIMÄE, R R, J M, P P, T J, P A. (2009). Plasma visfatin and ghrelin response to prolonged sculling in competitive male rowers. Medicine & Science in Sports & Exercise. 41(1).
  28. Vatani DS, Faraji H, Rahimi R, Ahmadizad S. (2011). Acute effect of exercise type on serum visfatin in healthy men. MED SPORT. 65:75-83.
  29. Plinta R, Olszanecka-Glinianowicz M, Drosdzol-Cop A, Chudek J, Skrzypulec-Plinta V. (2012). The effect of three-month pre-season preparatory period and short-term exercise on plasma leptin, adiponectin, visfatin, and ghrelin levels in young female handball and basketball players. J Endocrinol Investig. 35(6):595-601.
  30. Rudwill F, Blanc S, Gauquelin-Koch G, Chouker A, Heer M, Simon C, et al. (2013). Effects of different levels of physical inactivity on plasma visfatin in healthy normal-weight men. Applied Physiology, Nutrition, and Metabolism. 38(999):1-5.
  31. Ahmadizad S, Tahmasebi W, Bassami M, Sajadi M, Fathi I. (1391). Effects of progressive resistance training on plasma visfatin, insulin resistance and effective hormoneson visfatin.
  32. Paolisso G, Rizzo MR, Mazziotti G, Tagliamonte MR, Gambardella A, Rotondi M, et al. (1998). Advancing age and insulin resistance: role of plasma tumor necrosis factor-α. American Journal of Physiology-Endocrinology And Metabolism. 275(2): E294-E9.
  33. Marton O, Koltai E, Nyakas C, Bakonyi T, Zenteno-Savin T, Kumagai S, et al. (2010). Aging and exercise affect the level of protein acetylation and SIRT1 activity in cerebellum of male rats. Biogerontology. 11(6):679-86.
  34. Szoke E, Shrayyef MZ, Messing S, Woerle HJ, van Haeften TW, Meyer C, et al. (2008). Effect of Aging on Glucose Homeostasis Accelerated deterioration of β-cell function in individuals with impaired glucose tolerance. Diabetes Care. 31(3):539-43.
  35. Wolden-Hanson T, Marck BT, Smith L, Matsumoto AM. (1999). Cross-sectional and longitudinal analysis of age-associated changes in body composition of male Brown Norway rats: association of serum leptin levels with peripheral adiposity. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 54(3):B99-B107.
  36. Sacheck JM, Cannon JG, Hamada K, Vannier E, Blumberg JB, Roubenoff R. (2006). Age-related loss of associations between acute exercise-induced IL-6 and oxidative stress. American Journal of Physiology-Endocrinology And Metabolism. 291(2):E340-E9.
  37. Oki K, Yamane K, Kamei N, Nojima H, Kohno N. (2007). Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clinical endocrinology.67(5):796-800.
  38. Kim J-Y, Bae Y-H, Bae M-K, Kim S-R, Park H-J, Wee H-J, et al. (2009). Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research.1793(11): 1759-67.
  39. Jackson A, Pollock M. (2004). Generalized equations for predicting body density of men. 1978. The British journal of nutrition. 91(1):161.
  40. Dill D, Costill DL. (1974). Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol.37(2):247-8.
  41. Wallace TM, Levy JC, Matthews DR. (2004). Use and abuse of HOMA modeling. Diabetes Care. 27(6):1487-95.
  42. Ghanbari-Niaki A, Saghebjoo M, Soltani R, Kirwan JP. (2010). Plasma visfatin is increased after high-intensity exercise. Annals of Nutrition and Metabolism. 57(1):3-8.
  43. Davidson MB. (1979). The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly. Metabolism. 28(6):688-705.
  44. Lee DH. Sirt1 as a New Therapeutic Target in Metabolic and Age-Related Diseases. Chonnam Medical Journal. 2010;46(2):67-73.
  45. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, et al. (2009). STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol.11(4):492-500.
  46. Gomez CR, Karavitis J, Palmer JL, Faunce DE, Ramirez L, Nomellini V, et al. (2010). Interleukin-6 contributes to age-related alteration of cytokine production by macrophages. Mediat Inflamm.
  47. Mahbub S, Deburghgraeve CR, Kovacs EJ. (2012). Advanced age impairs macrophage polarization. J Interferon Cytokine Res. 32(1):18-26.
  48. Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, et al. (2005). Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol. 185(3):R1-R8.

فایل ها

سابقه مقاله

  • تاریخ دریافت: 27 اردیبهشت 1394
  • تاریخ بازنگری: 08 اردیبهشت 1403
  • تاریخ پذیرش: 11 دی 1399
  • تاریخ اولین انتشار: 11 دی 1399
  • تاریخ انتشار: 01 اردیبهشت 1392

هم رسانی

ارجاع به این مقاله

آمار